This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Axitinib (ATC: L01EK01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or
339 days left to bid. Opened 1 years ago, deadline 29 Apr 2027.
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent
Procurement of medical-grade surgical consumables to support operating theatre operations and patient care delivery.
Supply of orthopedic theatre implants and consumable materials under the Total Orthopaedic Solutions 3 Framework agreement.
Re-procurement of ophthalmic surgical consumables including IOLs, phacoemulsification, and vitreoretinal supplies for continued patient care delivery.
NHS trust seeking lymphoedema garment and accessory suppliers for a 3-year contract starting April 2027, with market engagement event on 16 June 2026.
